Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 106 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Lurbinectedin in addition to doxorubicin for small-cell lung cancer after prior platinum-containing therapy	Doxorubicin (Livatag; BA-003; Caelyx; Sarcodoxome; SP-1049C; Resmycin; JNS002; doxorubicin hydrochloride) , Lurbinectedin (PM01183; Zepzelca)	Small-cell lung cancer (SCLC)	Lung and Respiratory Cancer	2020	View \| Download
Lorlatinib for advanced ALK-positive non-small cell lung cancer – first line	Lorlatinib (PF-06463922; Lorviqua)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2020	View \| Download
Lorlatinib (PF-06463922) for advanced ALK or ROS1 positive non-small cell lung cancer – second line	Lorlatinib (PF-06463922; Lorviqua)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2017	View \| Download
Listeria monocytogenes vaccine for unresectable malignant plural mesothelioma	CRS-207	Malignant pleural mesothelioma (MPM)	Lung and Respiratory Cancer	2017	View \| Download
Lenvatinib with pembrolizumab for previously treated metastatic non-small cell lung cancer	Lenvatinib (Kisplyx; E7080; lenvatinib mesilate) , Pembrolizumab (Keytruda; MK-3475)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2022	View \| Download
Lazertinib with amivantamab and platinum-based chemotherapy for EGFR-mutated locally advanced or metastatic non-small-cell lung cancer after osimertinib failure	Amivantamab (JNJ-6372; JNJ-61186372) , Lazertinib , Platinum-based chemotherapy	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2022	View \| Download
Entrectinib for ROS1 fusion positive, locally advanced or metastatic non-small cell lung cancer	Entrectinib (RXDX-101)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2018	View \| Download
Encorafenib with binimetinib for treating metastatic BRAF V600E mutant non-small-cell lung cancer	Binimetinib (MEK162; MEK-162; ARRY-162) , Encorafenib (LGX818)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2022	View \| Download
Encorafenib with binimetinib for treating metastatic BRAF V600 mutant non-small-cell lung cancer	Binimetinib (MEK162; MEK-162; ARRY-162) , Encorafenib (LGX818)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2023	View \| Download
Durvalumab with tremelimumab for limited stage small-cell lung cancer	Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) , Tremelimumab (CP-675206; CP-675 206)	Small-cell lung cancer (SCLC)	Lung and Respiratory Cancer	2022	View \| Download